Skip to main content
. 2006 Sep 1;56(5):627–640. doi: 10.1007/s00262-006-0220-0

Fig. 2.

Fig. 2

Combined treatment of A498 kidney cancer cells with bv-sPLA2 and PtdIns(3,4)P2 inhibits phosphorylation of PKB/Akt. Cells were left untreated (C control), were treated with bv-sPLA2 (200 μg/ml), with PtdIns(3,4)P2 (200 μM) with EGF (50 ng/ml) or a combination thereof as indicated. Phosphorylation of serine 473 of PKB/Akt was normalised to total PKB/Akt levels and was quantitatively determined by specific ELISA. Shown are normalised mean values ± SEM of four independent experiments